These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: A randomized clinical trial to assess anti-plaque effects of an oral hygiene regimen with a stannous-containing sodium fluoride dentifrice, advanced manual toothbrush, and CPC rinse.
    Author: Feng X, He T, Cao M, He Y, Ji N.
    Journal: Am J Dent; 2016 Apr; 29(2):120-4. PubMed ID: 27295871.
    Abstract:
    PURPOSE: To assess the anti-plaque efficacy of an oral hygiene regimen comprised of a stannous-containing sodium fluoride dentifrice, advanced manual toothbrush, and a cetylpyridinium chloride (CPC) rinse compared to a negative control regimen. METHODS: This was a 4-week randomized and controlled, parallel group, single-center, single- blind, clinical trial in generally healthy Chinese adults with existing dental plaque. Following a 1-week acclimation period and cessation of overnight oral hygiene prior to the baseline examination, overnight pre-brushing plaque levels were assessed via digital plaque imaging analysis (DPIA). Subjects were randomly assigned to either: (1) the test regimen of a stannous-containing sodium fluoride dentifrice (Crest Pro-Health Expert), an advanced manual toothbrush with CrissCross bristles (Crest Pro-Health manual toothbrush), and a 0.07% CPC rinse (Crest Pro-Health Multi-Protection); or (2) the negative control regimen group, a 0.243% sodium fluoride dentifrice (Crest Cavity Protection) and a soft flat trim manual toothbrush (Crest MeiLiLiangJie). Subjects returned at Week 2 and Week 4 following twice daily use of their assigned products, again following pre-visit cessation of overnight oral hygiene, for DPIA evaluation of overnight plaque levels. RESULTS: 35 fully evaluable subjects completed the trial. At Week 2, the pre-brushing overnight average DPIA plaque scores for the advanced products regimen group were 72.4% statistically significantly lower relative to the control group (P< 0.0001). At Week 4, the mean plaque inhibition benefit provided by the regimen group was 76.8% greater than the control group (P< 0.0001). All products were well-tolerated. (Am J Dent 2016;29:120-124)
    [Abstract] [Full Text] [Related] [New Search]